MoneyWorks4Me

Cipla’s Bengaluru manufacturing facility classified as VAI by USFDA

05 Aug 2025 Evaluate

United States Food and Drug Administration (USFDA) has classified current Good Manufacturing Practices (cGMP) inspection conducted at Cipla’s manufacturing facility located in Bommasandra, Bengaluru as Voluntary Action Indicated (VAI). USFDA had conducted the inspection at said facility from May 26 to May 30, 2025.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Peers
Company Name CMP
Sun Pharma. Inds. 1844.20
Dr. Reddys Labs. 1225.40
Cipla 1390.00
Lupin 2071.70
Zydus Lifesciences 1216.25
View more..